Skip to main content
. 2022 Mar 18;12:844144. doi: 10.3389/fonc.2022.844144

Figure 7.

Figure 7

The potential ITGA5-involved immune checkpoints treatment and chemotherapeutic targets in gliomas. (A) Correlations between ITGA5 and seven types of immune checkpoints levels in gliomas. *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001. (B) The box plots of the estimated IC50 for several chemotherapeutic drugs among high-ITGA5 and low-ITGA5 groups.